Key biopharmaceutical properties affecting developability of a drug for enteral delivery. The properties are shown as hurdles to be surmounted if a dosage form is to achieve effective systemic delivery. Poor biopharmaceutical properties may sometimes be corrected by formulation, but at a cost in time and resources. Poor solubility and stability may be amenable to being fixed by formulation.
Poor permeability is difficult to correct by formulation.
First-pass metabolism problems are difficult to fix by oral formulation.